| In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models KP Hoeflich, C O'Brien, Z Boyd, G Cavet, S Guerrero, K Jung, T Januario, ... Clinical Cancer Research 15 (14), 4649-4664, 2009 | 585 | 2009 |
| Evaluation of circulating tumor cells and circulating tumor DNA in non–small cell lung cancer: Association with clinical endpoints in a phase II clinical trial of pertuzumab … EA Punnoose, S Atwal, W Liu, R Raja, BM Fine, BGM Hughes, RJ Hicks, ... Clinical Cancer Research 18 (8), 2391-2401, 2012 | 505 | 2012 |
| Facilitation of synaptic transmission by EGL-30 Gqα and EGL-8 PLCβ: DAG binding to UNC-13 is required to stimulate acetylcholine release MR Lackner, SJ Nurrish, JM Kaplan Neuron 24 (2), 335-346, 1999 | 389 | 1999 |
| Molecular biomarker analyses using circulating tumor cells EA Punnoose, SK Atwal, JM Spoerke, H Savage, A Pandita, RF Yeh, ... PloS one 5 (9), e12517, 2010 | 366 | 2010 |
| TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer S Stinson, MR Lackner, AT Adai, N Yu, HJ Kim, C O’Brien, J Spoerke, ... Science signaling 4 (177), ra41-ra41, 2011 | 327 | 2011 |
| First-in-human phase I study of pictilisib (GDC-0941), a potent pan–class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors D Sarker, JE Ang, R Baird, R Kristeleit, K Shah, V Moreno, PA Clarke, ... Clinical cancer research 21 (1), 77-86, 2015 | 311 | 2015 |
| Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant JM Spoerke, S Gendreau, K Walter, J Qiu, TR Wilson, H Savage, J Aimi, ... Nature communications 7 (1), 11579, 2016 | 305 | 2016 |
| Predictive biomarkers of sensitivity to the phosphatidylinositol 3′ kinase inhibitor GDC-0941 in breast cancer preclinical models C O'Brien, JJ Wallin, D Sampath, D GuhaThakurta, H Savage, ... Clinical cancer research 16 (14), 3670-3683, 2010 | 301 | 2010 |
| GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway JJ Wallin, KA Edgar, J Guan, M Berry, WW Prior, L Lee, JD Lesnick, ... Molecular cancer therapeutics 10 (12), 2426-2436, 2011 | 291 | 2011 |
| Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 … IE Krop, IA Mayer, V Ganju, M Dickler, S Johnston, S Morales, DA Yardley, ... The lancet oncology 17 (6), 811-821, 2016 | 289 | 2016 |
| Genetic alterations and oncogenic pathways associated with breast cancer subtypes X Hu, HM Stern, L Ge, C O'Brien, L Haydu, CD Honchell, PM Haverty, ... Molecular cancer research 7 (4), 511-522, 2009 | 288 | 2009 |
| A MAP kinase homolog, mpk-1, is involved in ras-mediated induction of vulval cell fates in Caenorhabditis elegans. MR Lackner, K Kornfeld, LM Miller, HR Horvitz, SK Kim Genes & development 8 (2), 160-173, 1994 | 265 | 1994 |
| MAP kinase signaling specificity mediated by the LIN-1 Ets/LIN-31 WH transcription factor complex during C. elegans vulval induction PB Tan, MR Lackner, SK Kim Cell 93 (4), 569-580, 1998 | 258 | 1998 |
| ERK inhibition overcomes acquired resistance to MEK inhibitors G Hatzivassiliou, B Liu, C O'Brien, JM Spoerke, KP Hoeflich, PM Haverty, ... Molecular cancer therapeutics 11 (5), 1143-1154, 2012 | 249 | 2012 |
| Analytical validation of a hybrid capture–based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA TA Clark, JH Chung, M Kennedy, JD Hughes, N Chennagiri, DS Lieber, ... The Journal of Molecular Diagnostics 20 (5), 686-702, 2018 | 214 | 2018 |
| Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein … KP Hoeflich, S Herter, J Tien, L Wong, L Berry, J Chan, C O'Brien, ... Cancer research 69 (7), 3042-3051, 2009 | 214 | 2009 |
| Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models JM Spoerke, C O'Brien, L Huw, H Koeppen, J Fridlyand, RK Brachmann, ... Clinical cancer research 18 (24), 6771-6783, 2012 | 204 | 2012 |
| Mechanisms of acquired resistance to targeted cancer therapies MR Lackner, TR Wilson, J Settleman Future oncology 8 (8), 999-1014, 2012 | 200 | 2012 |
| Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy J Zha, MR Lackner Clinical Cancer Research 16 (9), 2512-2517, 2010 | 183 | 2010 |
| miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer S Stinson, MR Lackner, AT Adai, N Yu, HJ Kim, C O’Brien, J Spoerke, ... Science signaling 4 (186), pt5-pt5, 2011 | 181 | 2011 |
